Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 139

Sort by

Sort Order Select

Journal Articles

Guardians of the tumor microenvironment: the neutrophil saga

Samir Parekh

Blood (2025) 146 (20): 2373–2374.

https://doi.org/10.1182/blood.2025030664

Published: 2025

Journal Articles

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Christine Ryan, Victoria Wang, Mitchell Smith, Brian Till, Samir Parekh, David Yang, Lale Kostakoglu, Nizar Abdel Samad, Opeyemi Jegede, Richard Little, Jonathan Friedberg, John Leonard, Brad Kahl, Peter Martin

Blood (2025) 146 (Supplement 1): 3581.

https://doi.org/10.1182/blood-2025-3581

Published: 2025

Journal Articles

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Blood (2025) 146 (Supplement 1): 2179.

https://doi.org/10.1182/blood-2025-2179

Published: 2025

Journal Articles

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

Blood (2025) 146 (Supplement 1): 916.

https://doi.org/10.1182/blood-2025-916

Published: 2025

Journal Articles

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Blood (2025) 146 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2025-5801

Published: 2025

Journal Articles

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Wanxing Zhang, Chaitanya Acharya, Steven Foltz, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, George Mulligan

Blood (2025) 146 (Supplement 1): 7470.

https://doi.org/10.1182/blood-2025-7470

Published: 2025

Journal Articles

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Blood (2025) 146 (Supplement 1): 2290.

https://doi.org/10.1182/blood-2025-2290

Published: 2025

Journal Articles

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study

Blood (2025) 146 (Supplement 1): 92.

https://doi.org/10.1182/blood-2025-92

Published: 2025

Journal Articles

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Blood (2025) 146 (Supplement 1): 3949.

https://doi.org/10.1182/blood-2025-3949

Published: 2025

Journal Articles

Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.

Adolfo Aleman, Rudra Prasad Dutta, Oliver Van Oekelen, David Melnekoff, Tarek Mouhieddine, Leah Grossman, Sidorela Reci, Shriya Desai, Patrick Brunner, Alessandro Lagana, Sundar Jagannath, Joshua Brody, Samir Parekh

Blood (2025) 146 (Supplement 1): 3946.

https://doi.org/10.1182/blood-2025-3946

Published: 2025

Journal Articles

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Blood (2025) 146 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2025-5731

Published: 2025

Journal Articles

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Blood (2025) 146 (Supplement 1): 5723.

https://doi.org/10.1182/blood-2025-5723

Published: 2025

Journal Articles

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Steven Foltz, Reyka Jayasinghe, MMRF Immune Atlas Network, David Avigan, Samir Parekh, Ravi Vij, Shaji Kumar, Taxiarchis Kourelis, Sagar Lonial, Hearn Cho, Ioannis Vlachos, Sacha Gnjatic, Li Ding, Manoj Bhasin, Chaitanya Acharya, Alexander Gout, George Mulligan

Blood (2025) 146 (Supplement 1): 4024.

https://doi.org/10.1182/blood-2025-4024

Published: 2025

Journal Articles

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

Maria Victoria del Rosal, Saoirse Bodnar, Tehilla Brander, Madeline Katz, Whilhelm Genthe, Kenan Onel, Sundar Jagannath, Alessandro Lagana, Samir Parekh, Santiago Thibaud

Blood (2025) 146 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2025-2151

Published: 2025

Journal Articles

Epigenetic targeting of SETD8 in multiple myeloma

Rudra Prasad Dutta, He Chen, Yue Zhong, Anqi Ma, Adolfo Aleman, Alison Park, Shriya Desai, Sidorela Reci, Ivan Odak, Ioanna Tsialta, Kedwin Ventura, H. Ümit Kaniskan, Alessandro Lagana, Jian Jin, Samir Parekh

Blood (2025) 146 (Supplement 1): 3310.

https://doi.org/10.1182/blood-2025-3310

Published: 2025

Journal Articles

Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies

Mujahid Quidwai, Santiago Thibaud, Sundar Jagannath, Samir Parekh, Alessandro Lagana

Blood (2025) 146 (Supplement 1): 2646.

https://doi.org/10.1182/blood-2025-2646

Published: 2025

Journal Articles

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Blood (2025) 146 (Supplement 1): 3996.

https://doi.org/10.1182/blood-2025-3996

Published: 2025

Journal Articles

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

Blood (2025) 146 (7): 819–833.

https://doi.org/10.1182/blood.2024025536

Published: 2025

Includes: Supplemental data

Journal Articles

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Lucia Y Chen, Michael Amatangelo, Adolfo Aleman, Oliver Van Oekelen, Tania Nevers, Yongliang Sun, William E. Pierceall, Katerina Kappes, Anna Blangiardo, Sundar Jagannath, Cesar Rodriguez, Samir Parekh

Blood (2024) 144 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2024-211651

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Guardians of the tumor microenvironment: the neutrophil saga

Prognostic impact of Mantle Cell Lymphoma frontline induction response assessments in the ECOG-ACRIN E1411 study of bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.

An immune proteomic atlas of 300 million bone marrow cells reveals prognostic cell states in multiple myeloma

Commpass explorer: An interactive platform to explore clinico-genomic data from newly diagnosed multiple myeloma patients from the commpass observational trial

Prolonged cytopenias after BCMA CAR‑T are associated with impaired endogenous T cell recovery characterized by decreased CD8+ T cell diversity

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study

Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy

Genomic alterations in TET2 and EZH2 serve as critical drivers of clonal malignant evolution in anti-BCMA CAR-T therapy for multiple myeloma.

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Shared immune features correspond to high-risk multiple myeloma across multiple human subtypes and murine models

Mapping the immune checkpoint receptor-ligand landscape in newly diagnosed multiple myeloma may help prioritize patients for immune checkpoint inhibitor therapy

Selective germline testing in multiple myeloma patients yields a six-fold increase in actionable cancer predisposition findings: Time for screening guidelines?

Epigenetic targeting of SETD8 in multiple myeloma

Oncodif: An auditable AI framework for automated genomic curation and natural-language clinical querying in hematologic malignancies

Development of predictive relapse indicators for myeloma T cell engagers (PRIME) model for myeloma patients receiving BCMA- and GPRC5D-targeting T cell engagers

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cells

Elotuzumab-Iberdomide-Dexamethasone Combination Therapy Activates T and NK Cells within the Immune Microenvironment of Multiple Myeloma Patients

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only